Safety of Using Fenofibrate with Repatha (Evolocumab)

Mechanism of Action and Safety Profile

The American College of Cardiology notes that evolocumab (Repatha) is a monoclonal antibody that targets PCSK9 protein, increasing the number of LDL receptors available to clear circulating LDL-C 1
Fenofibrate works through a different mechanism, acting as a peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist to primarily reduce triglycerides and modestly increase HDL cholesterol, as reported by the American Heart Association in Circulation 2, 3
The American Heart Association in Circulation recognizes that, unlike the combination of statins with gemfibrozil, fenofibrate does not have known interactions with PCSK9 inhibitors like evolocumab 2

The American College of Cardiology recommends that various lipid-lowering therapies may be used in combination when clinically indicated, according to the 2022 ACC Expert Consensus Decision Pathway 1
The American College of Cardiology suggests that fenofibrate is specifically mentioned as an appropriate agent to combine with other lipid-lowering therapies in patients with mixed hyperlipidemia, as stated in the 2022 ACC Expert Consensus Decision Pathway 1

The American College of Cardiology indicates that combination therapy may be appropriate in patients with mixed dyslipidemia (elevated LDL-C and triglycerides) 1, 4
The American College of Cardiology recommends that combination therapy may be considered in patients who fail to meet target lipid goals on monotherapy 4, 3
The American College of Cardiology suggests that combination therapy may be appropriate for patients with very high cardiovascular risk requiring intensive lipid management, as reported in Metabolism: Clinical and Experimental 5
The American Heart Association in Circulation notes that combination therapy may be considered when triglyceride levels remain elevated despite statin or PCSK9 inhibitor therapy 5, 6

The American College of Cardiology recommends monitoring lipid parameters regularly to assess efficacy of the combination therapy 7
The American College of Cardiology suggests checking renal function before initiating fenofibrate, within 3 months after initiation, and every 6 months thereafter 7
The American College of Cardiology advises that fenofibrate should be avoided or dose-adjusted in patients with moderate to severe renal impairment (eGFR <30 mL/min/1.73 m²) 7
The American Heart Association in Circulation recommends monitoring for muscle symptoms, although the risk of myopathy is significantly lower with fenofibrate-PCSK9 inhibitor combinations than with gemfibrozil-statin combinations 2

The American Heart Association in Circulation warns that gemfibrozil has significant drug interactions with many statins and should be avoided in combination therapy 2
The American Heart Association in Circulation notes that fenofibrate has a more favorable drug interaction profile and is the preferred fibrate when combination therapy is needed 2
The American College of Cardiology suggests that the 2017 ACC Expert Consensus specifically notes that fenofibrate may be considered with other lipid-lowering therapies when clinically indicated 4

Adding fenofibrate can provide additional triglyceride-lowering benefits when triglycerides remain elevated despite PCSK9 inhibitor therapy, as reported in Metabolism: Clinical and Experimental and Arteriosclerosis, Thrombosis, and Vascular Biology 5, 3